26,224 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Purchased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC acquired a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,224 shares of the company’s stock, valued at approximately $818,000.

Other institutional investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its position in Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after purchasing an additional 4,732 shares during the period. Focus Partners Wealth lifted its holdings in shares of Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares during the period. Franklin Resources Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $255,000. American Century Companies Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 14.2% in the second quarter. American Century Companies Inc. now owns 260,808 shares of the company’s stock valued at $4,371,000 after buying an additional 32,388 shares in the last quarter. Finally, Prudential Financial Inc. grew its holdings in Teva Pharmaceutical Industries by 62.2% during the second quarter. Prudential Financial Inc. now owns 96,488 shares of the company’s stock worth $1,617,000 after acquiring an additional 36,983 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $30.11 on Friday. The stock has a fifty day moving average price of $32.15 and a 200 day moving average price of $27.78. The stock has a market cap of $34.63 billion, a PE ratio of 25.10, a P/E/G ratio of 10.13 and a beta of 0.76. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 1,127 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the transaction, the insider directly owned 10,914 shares in the company, valued at approximately $345,646.38. This trade represents a 9.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the transaction, the insider owned 224,940 shares of the company’s stock, valued at approximately $6,779,691.60. The trade was a 21.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 920,901 shares of company stock worth $30,056,789. 0.49% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TEVA. Barclays increased their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Jefferies Financial Group raised their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, The Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.